Definition of the Concept of Super-responders in Atopic Dermatitis: A Spanish Delphi Consensus
DOI:
https://doi.org/10.2340/actadv.v105.42240Keywords:
atopic dermatitis, biological agents, Delphi consensus, Janus kinase inhibitorsAbstract
A consensus study of experts was conducted to establish a definition of the concept of super-responders (SR) in atopic dermatitis (AD). The study employed a Delphi methodology based on 2 rounds to define the concept of SR in AD, exploring the opinions of expert dermatologists in AD from across Spain regarding a series of statements developed after a systematic review. Consensus was predefined as an agreement of ≥ 80% among all respondents. In the first round, 4 statements reached consensus. In the second round, 2 additional statements reached consensus. To illustrate these definitions, a set of practical cases was provided, and the level of agreement among experts was evaluated. According to the agreed statements, time is important when defining the achievable response as SR. The concept of SR should associate a rapid response (before week 16), include both symptom variables, such as the Eczema Area and Severity Index and Investigators Global Assessment (IGA) and patient-reported outcomes, including pruritus or the Patient-Oriented Eczema Measure. This concept should be associated with complete or nearly complete clearance of lesions (IGA 0–1), and with sustained responses over time (at week 52). Mild flares (IGA ≤ 2) may occur without varying according to the patient’s age.
Downloads
References
Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primer 2018; 4: 1.
https://doi.org/10.1038/s41572-018-0001-z DOI: https://doi.org/10.1038/s41572-018-0001-z
Sesi J, Feldman SR. Comparative efficacy of systemic treatments for atopic dermatitis in adults. Expert Rev Clin Immunol 2024; 20: 313-320.
https://doi.org/10.1080/1744666X.2023.2291038 DOI: https://doi.org/10.1080/1744666X.2023.2291038
Mastorino L, Susca S, Cariti C, Verrone A, Stroppiana E, Ortoncelli M, et al. "Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors. Exp Dermatol 2023; 32: 2187-2188.
https://doi.org/10.1111/exd.14731 DOI: https://doi.org/10.1111/exd.14731
Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry. Allergy 2020; 75: 116-126.
https://doi.org/10.1111/all.14080 DOI: https://doi.org/10.1111/all.14080
Canonica GW, Bourdin A, Peters AT, Desrosiers M, Bachert C, Weidinger S, et al. Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases. J Allergy Clin Immunol Pract 2022; 10: 1515-1526.
https://doi.org/10.1016/j.jaip.2022.02.026 DOI: https://doi.org/10.1016/j.jaip.2022.02.026
Silverberg JI, Simpson EL, Boguniewicz M, De Bruin-Weller MS, Foley P, Kataoka Y, et al. Dupilumab provides rapid and sustained clinically meaningful responses in adults with moderate-to-severe atopic dermatitis. Acta Derm Venereol 2021; 101: adv00585.
https://doi.org/10.2340/actadv.v101.307 DOI: https://doi.org/10.2340/actadv.v101.307
Paller AS, Bansal A, Simpson EL, Boguniewicz M, Blauvelt A, Siegfried EC, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol 2020; 21: 119-131.
https://doi.org/10.1007/s40257-019-00478-y DOI: https://doi.org/10.1007/s40257-019-00478-y
Silverberg JI, Gooderham MJ, Katoh N, Aoki V, Pink AE, Binamer Y, et al. 53959 Treatment with upadacitinib increases the achievement of minimal disease activity among patients with moderate-to-severe atopic dermatitis: results from phase 3 studies (Measure Up 1 and Measure Up 2). J Am Acad Dermatol 2024: 91; AB94.
https://doi.org/10.1016/j.jaad.2024.07.379 DOI: https://doi.org/10.1016/j.jaad.2024.07.379
Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs 2000; 32: 1008-1015.
https://doi.org/10.1046/j.1365-2648.2000.t01-1-01567.x DOI: https://doi.org/10.1046/j.1365-2648.2000.t01-1-01567.x
Gattrell WT, Logullo P, van Zuuren EJ, Price A, Hughes EL, Blazey P, et al. ACCORD (ACcurate COnsensus Reporting Document): A reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLOS Med 2024; 21: e1004326.
https://doi.org/10.1371/journal.pmed.1004326 DOI: https://doi.org/10.1371/journal.pmed.1004326
Ruiz-Villaverde R, Domínguez-Cruz J, Navarro-Triviño FJ, Galán-Gutiérrez M, Armario-Hita JC, Pereyra-Rodriguez JJ. Atopic dermatitis: background, objectives and future perspectives (superresponders). Life 2022; 12:1192.
https://doi.org/10.3390/life12081192 DOI: https://doi.org/10.3390/life12081192
Alegre-Bailo A, Sánchez-Gilo A, Román Mendoza NM, Mateos-Rico JJ, Vicente-Martín FJ. Tralokinumab treatment in atopic dermatitis: depicting super-responders. J Dermatol 2023; 50:1650-1652.
https://doi.org/10.1111/1346-8138.17009 DOI: https://doi.org/10.1111/1346-8138.17009
Reich K, Armstrong AW, Eyrich K, Hong CH, Gooderman M, Blauvelt A, et al. Achievement of super-response ver time in patients with moderate-to-severe atopic dermatitis treated with abrocitinib versus dupilumab: a post-hoc analysis of head-to-head phase 3 JADE DARE study. European Academy of Dermatology and Venereology Congress 2023 Oct 11-14. Berlin, Germany. Abstract No 1167
Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2021; 157: 1047-1055.
https://doi.org/10.1001/jamadermatol.2021.3023 DOI: https://doi.org/10.1001/jamadermatol.2021.3023
Silverberg, JI, Bunick C, Hong HC-h, Mendes-Basto P, Stein Gold L, Costanzo A, et al. 734 - Efficacy and safety of upadacitinib vs dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up). Br j Dermatol 2024; 191: ljae266.107.
https://doi.org/10.1093/bjd/ljae266.107 DOI: https://doi.org/10.1093/bjd/ljae266.107
Montero-Vilchez T, Montero-Vilchez C, Garrido-Colmenero C, Sanabria de la Torre R, Arias-Santiago S. Minimal disease activity in patients with atopic dermatitis treated with upadacitinib: a prospective observational study. EADV Symposium 2024 May 16-18. St. Julian's, Malta. Abstract No 898.
Limão R, Brás R, Pedro E, Silva SL, Lopes A. Dupilumab in patients with atopic dermatitis: assessing treatment response, clinical features, and potential biomarkers in real-life. Eur Ann Allergy Clin Immunol 2024 Apr 9. [Online ahead of print].
https://doi.org/10.23822/EurAnnACI.1764-1489.341 DOI: https://doi.org/10.23822/EurAnnACI.1764-1489.341
Fougerousse AC, Alexandre M, Darrigade AS, Merhand S, Marquié A, Hamza M, et al. Impact of atopic dermatitis on adult women's lives: a survey of 1,009 French women. Acta Derm Venereol 2024; 104: adv10321.
https://doi.org/10.2340/actadv.v104.10321 DOI: https://doi.org/10.2340/actadv.v104.10321
Silverberg JI, Simpson B, Abuabara K, Guttman-Yassky E, Calimlim B, Wegzyn C, et al. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort. J Am Acad Dermatol 2023; 89: 519-528.
https://doi.org/10.1016/j.jaad.2023.04.052 DOI: https://doi.org/10.1016/j.jaad.2023.04.052
Published
How to Cite
License
Copyright (c) 2025 Juan-Manuel Liñán-Barroso, Juan-Carlos Hernández-Rodríguez, Ricardo Ruiz-Villaverde, Manuel Galán-Gutiérrez, Francisco Navarro-Triviño, Javier Domínguez-Cruz, José-Carlos Armario-Hita, Jose-Juan Pereyra-Rodriguez
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
